瘤缩因子受体相关因子5通过表皮-介质细胞过渡来增强周围囊化的克罗恩病
Xiaomei Sun1, Hairui Gao2, Lu Lu3
1Department of Colorectal Surgery, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, the First Clinical Medical College, Nanjing, Jiangsu, China.
瘤坏死因子受体相关因子5 (TRAF5) 通过促进表皮-介质细胞转换 (EMT) 来驱动近管裂性克罗恩病 (PFCD). 减少TRAF5的表达缓解了PFCD的发展和相关的细胞变化.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 克罗恩氏病 (CD) 是一种慢性炎症性肠道疾病,对生活质量产生重大影响.
- 周围的CD (PFCD) 是CD的常见和具有挑战性的表现.
- 了解PFCD的分子基础对于改善管理至关重要.
研究的目的:
- 为了阐明驱动PFCD的分子机制.
- 为了确定PFCD的潜在生物标志物.
- 为了调查TRAF5在PFCD病变发生中的作用.
主要方法:
- 用转录组测序来比较PFCD和对照组.
- 量化聚合酶连锁反应 (qPCR) 和西部黑斑被用于检测基因和蛋白质表达.
- 免疫组织化学评估了TRAF5,E-cadherin,SNAIL1和vimentin的蛋白质水平.
- 在HT-29细胞中TRAF5倒置后,进行了细胞增殖和迁移试验.
主要成果:
- 转录基因分析显示,PFCD中TRAF5的显著上调.
- 在PFCD中观察到NF-κB和IL-13的mRNA水平升高.
- PFCD与TRAF5,SNAIL1和维丁的增加以及E-cadherin的减少有关,这表明表皮-介质细胞转变 (EMT).
- 抑制TRAF5降低了细胞增殖和迁移,抑制了NF-κB和IL-13,并促进了E-cadherin的表达.
结论:
- PFCD的发展与EMT有关.
- TRAF5被确定为PFCD病变发生的一个关键基因.
- TRAF5驱动PFCD通过EMT的进展,它的淘汰减轻了这一过程.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
08:37Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
The Tumor Microenvironment
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
